Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. (Q37691181)
Jump to navigation
Jump to search
scientific article published on January 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. |
scientific article published on January 2013 |
Statements
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer (English)
Mark Clemons
Christian F Singer
Rebecca A Dent
Hans Wildiers
Arlene Chan
Nicole J McCarthy
Elizabeth S Lowe
Claire L Watkins
James Carmichael
1 January 2013
1 reference